Picture of Amedisys logo

AMED — Amedisys News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeMid CapSuper Stock

Amedisys Inc expected to post earnings of $1.19 a share - Earnings Preview

* Amedisys Inc  AMED.OQ   AMED.O  is expected to show a rise
in
quarterly revenue when it reports  results on July 24
(estimated) for the period ending June 30 2024
    * The Baton Rouge Louisiana-based  company is expected to
report a
4.7% increase in revenue to $578.825 million from $552.97
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Amedisys Inc is for
earnings
of $1.19 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 9
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Amedisys
Inc is
$101.00​, above​ its last closing price of $97.60. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  1.03        1.02       1.03      Beat    1
 Dec. 31 2023  1.02        1.03       0.94      Missed  -8.9
 Jan. 1 0001   1.06        1.08       0.98      Missed  -9.2​
 Jun. 30 2023  1.09        1.09       1.37      Beat    25.5
 ​​Mar.        0.88        0.88       1.00      Beat    13.1
 31 2023                                                
 Dec. 31 2022  0.97        1.00       1.16      Beat    15.5​
 Sep. 30 2022  1.21        1.22       1.15      Missed  -5.5
 Jun. 30 2022  1.23        1.23       1.47      Beat    19.5
 This summary was machine generated July 22 at 12:47 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Amedisys

See all news